Quick answer: Published rat studies measured Semax-associated gene expression three ways: targeted qPCR for neurotrophins one hour after intranasal administration, a genome-wide biochip in the ischemic cortex, and RNA-seq at 4.5 and 24 hours with a 1.5-fold and adjusted-p cutoff. Each design answers a different question, so the headline numbers are not interchangeable. Laboratory research use only.
Why compare the methods before the genes
Reading the Semax expression literature as a list of up- and down-regulated genes misses the point that matters most to a laboratory: the studies used different techniques, regions, time points and thresholds, and those choices decide what can be concluded. This article is organized by method, not by gene. It is meant to help a reader judge a paper's numbers and plan comparable work with the Semax research peptide. The compound's background is in the Semax research overview, and its sequence and rationale are covered in what is Semax.
Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. Its first four residues correspond to ACTH(4-7), with a Pro-Gly-Pro tail that slows enzymatic breakdown. Every paper discussed here is a laboratory animal study, and none of them supports a claim about use outside the laboratory.
Method 1: targeted qPCR for neurotrophins
The simplest design asks about a short list of genes. In one study, male Wistar rats received a single intranasal application of Semax at 50 µg/kg and were analyzed one hour later by real-time PCR. Semax increased expression of both nerve growth factor (Ngf) and brain-derived neurotrophic factor (Bdnf) genes in the hippocampus, Bdnf expression also rose in the brainstem and cerebellum, and Ngf expression decreased in the frontal cortex [1]. The authors concluded that Semax induces rapid, gene- and region-specific changes in neurotrophin expression in normal rat brain.
A related study measured BDNF at the protein level and trkB phosphorylation after a single 50 µg/kg intranasal application, reporting a maximal 1.4-fold rise in BDNF protein, a 1.6-fold rise in trkB tyrosine phosphorylation, and 3-fold and 2-fold rises in exon III BDNF and trkB mRNA in the hippocampus [2]. Taken together, these two papers show how targeted qPCR is complemented by protein and phosphorylation readouts to build a case.
What targeted qPCR cannot do is discover. It reports on the genes chosen in advance, and the direction of change depends heavily on region and time. A decrease in Ngf in the frontal cortex alongside an increase in the hippocampus [1] is a warning against pooling brain regions.
Method 2: genome-wide biochip
Genome-wide arrays measure thousands of transcripts at once. In rats with focal cerebral ischemia, a biochip analysis of cortex from animals exposed with Semax or Pro-Gly-Pro identified differentially expressed genes and analyzed them with a pathway tool. The authors reported that the immune response was the process most affected, that Semax enhanced the antigen presentation signaling pathway, intensified the effect of ischemia on interferon signaling and affected immunoglobulin synthesis, and that Pro-Gly-Pro alone behaved differently from Semax [3]. A separate paper on the same model reported that both Semax and Pro-Gly-Pro activated transcription of neurotrophins and their receptors in the ischemic cortex, with Semax acting selectively and Pro-Gly-Pro acting more broadly [4].
Arrays are limited by probe design and dynamic range, but they were the workhorse of the first transcriptomic papers and remain useful for comparing with older data.
Method 3: RNA sequencing
Later work moved to RNA-seq. Under transient middle cerebral artery occlusion, an RNA-seq study found 394 differentially expressed genes (more than 1.5-fold change) in rat brain at 24 hours after occlusion in animals given Semax relative to saline, and reported that Semax suppressed inflammation-related genes and activated neurotransmission-related genes, in contrast to ischemia-reperfusion alone [5]. A study at 4.5 hours in the dorsolateral frontal cortex compared Semax with a second peptide, ACTH(6-9)PGP, and reported 131 and 322 differentially expressed genes respectively, along with partial prevention of ischemia-induced shifts in immune- and neurosignaling-related genes [6]. At 24 hours in the penumbra-associated frontal cortex, a follow-up reported 3,774 ischemia-related genes and 1,539 and 2,066 differentially expressed genes for Semax and ACTH(6-9)PGP, with 1,171 genes whose ischemia-induced distortions both peptides reduced [7].
Outside ischemia, hippocampal RNA-seq after acute restraint stress reported 1,359 differentially expressed genes in vehicle-exposed stressed rats at 4.5 hours, more than 1,500 with Semax and fewer than 400 with ACTH(6-9)PGP, with around 250 shared genes moving in the same direction [8].
Putting the designs side by side
| Study type | Tissue and model | Time point | Technique | Headline number |
|---|---|---|---|---|
| Neurotrophin qPCR [1] | Normal rat brain regions | 1 h | Real-time PCR | Bdnf, Ngf up in hippocampus |
| BDNF/trkB protein [2] | Rat hippocampus | Single application | Protein, phospho, mRNA | BDNF protein up to 1.4-fold |
| Ischemic cortex biochip [3] | Focal ischemia | Post-occlusion | Biochip | Immune response most affected |
| tMCAO RNA-seq [5] | Rat brain | 24 h | RNA-seq | 394 DEGs |
| tMCAO RNA-seq [6] | Frontal cortex | 4.5 h | RNA-seq | 131 DEGs (Semax) |
| tMCAO RNA-seq [7] | Penumbra frontal cortex | 24 h | RNA-seq | 1,539 DEGs (Semax) |
| Restraint stress [8] | Hippocampus | 4.5 h | RNA-seq | More than 1,500 DEGs (Semax) |
The 394 figure at 24 hours and the 1,539 figure at 24 hours in different papers show how much the count depends on the region sampled, the comparison made and the threshold, not on the peptide alone.
How the numbers get made
A differentially expressed gene count is the product of a pipeline, and each step shifts it. The cutoff matters: the RNA-seq papers above used a fold change above 1.5 and in several cases an adjusted p-value below 0.05 [7, 8]. A looser threshold gives more genes. The comparison matters too: Semax against saline, ischemia against sham and Semax against ischemia are three different contrasts, and a paper may report any of them. The sample matters: dissected cortical regions differ in cell-type composition, and a region-level change can reflect a shift in the proportion of cell types.
| Pipeline step | What can change the count |
|---|---|
| Tissue dissection | Region boundaries, cell-type mix |
| Time point | Transient changes appear or vanish |
| Library preparation | Depth, RNA integrity |
| Normalization | Which genes are regarded as stable |
| Fold-change cutoff | 1.5-fold versus 2-fold |
| Multiple-testing correction | Adjusted p versus raw p |
| Contrast | Semax vs saline, vs ischemia, vs comparator |
Designing a comparable experiment
A laboratory planning its own expression work with Semax can borrow from these papers without copying them:
1. Name the question first: a few known genes (qPCR) or discovery (RNA-seq). 2. Choose the region and write down the dissection method, because region-specific effects are central to the results above. 3. Choose time points deliberately; the published ones range from 1 hour to 24 hours. 4. Include a vehicle group handled identically, and, where relevant, a comparator peptide. 5. Pre-specify the cutoff and correction before looking at the data. 6. Validate a handful of RNA-seq hits by qPCR with independent animals.
Stock preparation is the quiet source of error. Concentration is vial mass divided by diluent volume, the amount per animal is the per-kilogram figure from a protocol multiplied by body mass in kilograms, and the volume is that amount divided by the stock concentration. The reconstitution calculator handles the first step; record all three figures. The peptide reconstitution volume calculations article explains the arithmetic, and Semax purity testing explains what to check on the certificate. The COA page shows where batch documentation is published.
What the expression literature cannot tell you
Gene expression is a molecular readout, not a functional outcome. A change in mRNA does not guarantee a change in protein, and a change in protein does not guarantee a change in behavior. Several of the cited groups overlap, so independence is limited, and all use rats, so cross-species statements are unsupported. The papers also report peptide-induced shifts against a baseline of strong ischemia- or stress-induced changes, which is a different thing from effects in unperturbed tissue. For this site's purposes the right summary is that Semax is a reproducible tool for studying how a short ACTH-derived peptide is associated with expression changes in rodent models, and nothing more. For more on its sibling peptide see the Selank research overview, and for the wider catalog use the shop.
Frequently asked questions
What techniques have been used to study Semax and gene expression?
Real-time PCR for specific neurotrophin genes, genome-wide biochips in ischemic cortex, and RNA-seq at 4.5 and 24 hours in ischemia and stress models.
What did the qPCR study report?
One hour after a single intranasal application at 50 µg/kg in rats, Bdnf and Ngf expression rose in the hippocampus, Bdnf rose in the brainstem and cerebellum, and Ngf fell in the frontal cortex.
Why do papers report different numbers of affected genes?
Region, time point, contrast, fold-change cutoff and multiple-testing correction all change the count, so counts from different papers are not directly comparable.
What is a differentially expressed gene?
A gene whose measured expression differs between two groups by more than a chosen fold change and statistical threshold.
Did Semax act the same way as Pro-Gly-Pro?
Not entirely. In ischemic cortex, the biochip and qPCR studies describe overlapping but distinct profiles, with Semax acting more selectively on neurotrophin genes.
What is ACTH(6-9)PGP?
A second synthetic ACTH-derived peptide compared with Semax in recent RNA-seq papers from the same research groups.
Does a change in mRNA mean a change in function?
No. mRNA, protein and behavior are separate levels, and each needs its own readout.
How should I plan a stock for an expression study?
Compute concentration as vial mass divided by diluent volume, convert per-kilogram amounts to per-animal amounts using body mass, and divide by concentration for the volume. The site calculator does the first step.
How is Semax stored?
At 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light, per the product page.
Do these studies apply outside the laboratory?
No claim is made. They are rodent studies, and the material is sold for laboratory research only.
Research-use statement
This product is supplied for laboratory research use only. It is not a drug, food or cosmetic, and it is not for human or animal consumption. This article compares published laboratory methods and does not recommend any application. Explore the research library for related material.
Related reading: Semax Intranasal Route in Preclinical Research Studies, Semax in Ischemia Models: What Mechanism Studies Show, Semax in Animal Models: A Model Selection Guide.
References
- Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Slominsky PA, Lymborska SA, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH4–10. Neuroscience Letters. 2007;417(2):201-205. doi:10.1016/j.neulet.2007.02.042
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108
- Medvedeva EV, Dmitrieva VG, Limborska SA, Myasoedov NF, Dergunova LV. Semax, an analog of ACTH(4−7), regulates expression of immune response genes during ischemic brain injury in rats. Mol Genet Genomics. 2017;292(3):635-653. doi:10.1007/s00438-017-1297-1
- Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia. Cell Mol Neurobiol. 2009;30(1):71-79. doi:10.1007/s10571-009-9432-0
- Filippenkov IB, Stavchansky VV, Denisova AE, Yuzhakov VV, Sevan’kaeva LE, Sudarkina OY, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats. Genes. 2020;11(6):681. doi:10.3390/genes11060681
- Filippenkov IB, Remizova JA, Stavchansky VV, Denisova AE, Gubsky LV, Myasoedov NF, et al. Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period. Genes. 2023;14(7):1382. doi:10.3390/genes14071382
- Filippenkov IB, Shpetko YY, Stavchansky VV, Denisova AE, Gubsky LV, Andreeva LA, et al. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. 2024;12(12):2830. doi:10.3390/biomedicines12122830
- Filippenkov IB, Stavchansky VV, Glazova NY, Sebentsova EA, Remizova JA, Valieva LV, et al. Antistress Action of Melanocortin Derivatives Associated with Correction of Gene Expression Patterns in the Hippocampus of Male Rats Following Acute Stress. IJMS. 2021;22(18):10054. doi:10.3390/ijms221810054
